179 related articles for article (PubMed ID: 18544421)
1. Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia.
Abshire T
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S3-6. PubMed ID: 18544421
[TBL] [Abstract][Full Text] [Related]
2. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.
Abshire T; Kenet G
Haemophilia; 2008 Sep; 14(5):898-902. PubMed ID: 18684126
[TBL] [Abstract][Full Text] [Related]
3. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
4. Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors.
Milošević D; Bilić E; Batinić D; Poropat M; Štern-Padovan R; Galić S; Turudić D
BMC Pediatr; 2014 Dec; 14():315. PubMed ID: 25515020
[TBL] [Abstract][Full Text] [Related]
5. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
O'Connell KA; Wood JJ; Wise RP; Lozier JN; Braun MM
JAMA; 2006 Jan; 295(3):293-8. PubMed ID: 16418464
[TBL] [Abstract][Full Text] [Related]
6. Use of recombinant factor VIIa in hereditary bleeding disorders.
Poon MC
Curr Opin Hematol; 2001 Sep; 8(5):312-8. PubMed ID: 11604567
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential.
Carr ME; Martin EJ
Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):661-74. PubMed ID: 15350168
[TBL] [Abstract][Full Text] [Related]
8. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
9. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
Gruppo RA; Malan D; Kapocsi J; Nemes L; Hay CRM; Boggio L; Chowdary P; Tagariello G; von Drygalski A; Hua F; Scaramozza M; Arkin S;
J Thromb Haemost; 2018 Oct; 16(10):1984-1993. PubMed ID: 30151972
[TBL] [Abstract][Full Text] [Related]
10. Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
Bykov K; Bohn RL; Ewenstein BM; Seeger JD; Avorn J; Bateman BT
Thromb Haemost; 2017 Dec; 117(12):2267-2273. PubMed ID: 29212114
[TBL] [Abstract][Full Text] [Related]
11. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
Nakar C; Cooper DL; DiMichele D
Haemophilia; 2010 Jul; 16(4):625-31. PubMed ID: 20158526
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting.
Logan AC; Goodnough LT
Hematology Am Soc Hematol Educ Program; 2010; 2010():153-9. PubMed ID: 21239786
[TBL] [Abstract][Full Text] [Related]
13. Unlabeled uses of factor VIIa (recombinant) in pediatric patients.
Hong I; Stachnik J
Am J Health Syst Pharm; 2010 Nov; 67(22):1909-19. PubMed ID: 21048207
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
Tiede A; Friedrich U; Stenmo C; Allen G; Giangrande P; Goudemand J; Hay C; Holmström M; Klamroth R; Lethagen S; McKenzie S; Miesbach W; Negrier C; Yuste VJ; Berntorp E
J Thromb Haemost; 2011 Jun; 9(6):1191-9. PubMed ID: 21489128
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia.
Morfini M; Bjerre J
Haemophilia; 2011 Nov; 17(6):860-6. PubMed ID: 21371194
[TBL] [Abstract][Full Text] [Related]
16. Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia.
Tiede A
Hamostaseologie; 2017; 37(4):307-310. PubMed ID: 29582931
[No Abstract] [Full Text] [Related]
17. Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent.
Hedner U; Brun NC
Neuroradiology; 2007 Oct; 49(10):789-93. PubMed ID: 17653706
[TBL] [Abstract][Full Text] [Related]
18. [Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].
Auerswald G; Muntean W; Kemkes-Matthes B; Klamroth R; Krause M; Kurnik K; Oldenburg J; Pabinger-Fasching I; Schramm W; Zimmermann R; Zotz RB
Hamostaseologie; 2009 May; 29(2):197-203. PubMed ID: 19404511
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with activated factor VII: focus on safety aspects.
Roberts HR
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S115-8. PubMed ID: 9819041
[TBL] [Abstract][Full Text] [Related]
20. Safety update on the use of recombinant activated factor VII in approved indications.
Neufeld EJ; Négrier C; Arkhammar P; Benchikh el Fegoun S; Simonsen MD; Rosholm A; Seremetis S
Blood Rev; 2015 Jun; 29 Suppl 1():S34-41. PubMed ID: 26073367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
